BeStock  
Stocks › BRVE

Braveheart Bio BRVE

US equityMarket cap rank #2809Biotechnology
$21.35 +$0.08 (+0.38%)
Market closed · Oct 6, 5:40 am ET · Last extended-hours $21.35 0.00%
Open$21.57
Prev close$21.27
Day range$19.83 – $22.02
Volume889.0K
Market cap$1.92B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q2, ended Jun 2026

Revenue$0.00
Operating profit-$15.88M-58,722.2% YoY
Net profit-$14.99M-3,833.9% YoY
Diluted EPS-$0.30-3,290.6% YoY

Revenue, last 4 quarters

$0.0Mar '25$0.0Jun '25$0.0Mar '26$0.0Jun '26

Net profit, last 4 quarters

$-99.0KMar '25$-381.0KJun '25$-14.3MMar '26$-15.0MJun '26

Diluted EPS by quarter

0.00Mar '25-0.01Jun '25-0.33Mar '26-0.30Jun '26

Profitability & balance sheet

Return on assets-73.9%
Current ratio17.03

Income statement

Line item 2026 Q2 2026 Q1 2025 Q2 2025 Q1
Diluted EPS -$0.30 -$0.33 -$0.01 -$0.00
Non-Operating Interest Income $889,000.00 $771,000.00 $0.00 $0.00
Net Non-Operating Interest Income (Expense) $889,000.00 $771,000.00 $0.00 $0.00
Operating Profit -$15.88M -$15.05M -$27,000.00 -$5,000.00
Research & Development $11.13M $10.91M $0.00 $0.00
-General & Admin Expense $4.76M $4.14M $27,000.00 $5,000.00
Selling and Admin Expenses $4.76M $4.14M $27,000.00 $5,000.00
Operating Expense $15.88M $15.05M $27,000.00 $5,000.00
Total Operating Revenue $0.00 $0.00 $0.00 $0.00
Other Income (Expense) $5,000.00 -$2,000.00 -$354,000.00 -$94,000.00
Profit from Continuing Operations -$14.99M -$14.28M -$381,000.00 -$99,000.00
Basic EPS -$0.30 -$0.33 -$0.01 -$0.00
Net Income to Common Stockholders -$18.60M -$14.28M -$381,000.00 -$99,000.00
Preferred Stock Dividends $3.62M – – –
Net Income to Parent Company -$14.99M -$14.28M -$381,000.00 -$99,000.00
Net Profit -$14.99M -$14.28M -$381,000.00 -$99,000.00
Pretax Profit -$14.99M -$14.28M -$381,000.00 -$99,000.00
Other Non-Operating Income (Expenses) $5,000.00 -$2,000.00 – –
Special Income (Charges) $0.00 $0.00 -$354,000.00 -$94,000.00
-Less:Other Special Charges – – $354,000.00 $94,000.00

Discussion

No comments yet — be the first to weigh in on BRVE.

Leave a comment

Scroll to Top